Orasure Technologies INC 10-Q quarterly reports

OraSure Technologies reported a 2% decrease in net revenues for Q2 2026 compared to the prior year, alongside a continued operating loss, though a significant non-cash gain from contingent consideration adjustments improved net income.

OraSure Technologies reports a net loss of $22.4 million for Q1 2026 as the company navigates a transition in its product portfolio and cost structure.

OraSure Technologies, Inc. reported a significant increase in net loss and a substantial revenue decline for the three and nine months ended September 30, 2025, driven by reduced demand for COVID-19 tests and lower international HIV revenues, despite strategic acquisitions and cost-cutting measures.

OraSure Technologies, Inc. reported a significant decrease in net revenues and a substantial increase in net loss for the second quarter and first half of 2025, driven by reduced COVID-19 testing demand and strategic business exits.

OraSure Technologies' Q1 2025 results reveal a significant revenue decrease primarily due to reduced COVID-19 test sales, alongside strategic adjustments including workforce reductions and business line discontinuations.

OraSure Technologies experienced a significant revenue decrease in Q3 2024, driven by reduced COVID-19 testing demand and strategic business restructuring.

OraSure Technologies experienced a significant revenue decrease in the second quarter of 2024, driven by reduced COVID-19 testing demand and strategic business restructuring.

OraSure Technologies experienced a significant revenue decrease in the first quarter of 2024, primarily due to reduced COVID-19 testing demand and strategic business changes.